Table 1:
Patient Characteristics
| Level II (4.0 Gy/fx) (n=8) |
Level III (4.5 Gy/fx) (n=7) |
Level IV (5.0 Gy/fx) (n=8) |
|
|---|---|---|---|
| Age (years) | |||
| Median | 59.5 | 52 | 73 |
| Min - Max | 54 – 85 | 42 – 74 | 30 – 79 |
| Sex | |||
| Male | 4 (50.0%) | 3 (42.9%) | 4 (50.0%) |
| Female | 4 (50.0%) | 4 (57.1%) | 4 (50.0%) |
| Race | |||
| Asian | 0 (0.0%) | 1 (14.3%) | 1 (12.5%) |
| White | 8 (100.0%) | 6 (85.7%) | 6 (75.0%) |
| Unknown | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) |
| Zubrod Performance Status | |||
| 0 | 5 (62.5%) | 6 (85.7%) | 5 (62.5%) |
| 1 | 3 (37.5%) | 1 (14.3%) | 3 (37.5%) |
| Number of Measurable Lesions | |||
| 1 | 4 (50.0%) | 5 (71.4%) | 5 (62.5%) |
| 2 | 1 (12.5%) | 2 (28.6%) | 1 (12.5%) |
| 3 | 3 (37.5%) | 0 (0.0%) | 2 (25.0%) |
| Size of Largest Lesion | |||
| >1–3 cm | 4 (50.0%) | 5 (71.4%) | 4 (50.0%) |
| >3–4 cm | 1 (12.5%) | 0 (0.0%) | 1 (12.5%) |
| >4–5 cm | 1 (12.5%) | 1 (14.3%) | 1 (12.5%) |
| >5–8 cm | 2 (25.0%) | 1 (0.0%) | 2 (25.0%) |
| Site of Primary Tumor | |||
| Colon/colorectal | 3 (37.5%) | 3 (42.9%) | 2 (25.0%) |
| Breast | 3 (37.5%) | 2 (28.6%) | 2 (25.0%) |
| Leiomyosarcoma | 0 (0.0%) | 1 (14.3%) | 1 (12.5%) |
| GE Junction | 1 (12.5%) | 0 (0.0%) | 0 (0.0%) |
| Liver | 1 (12.5%) | 0 (0.0%) | 0 (0.0%) |
| Pancreas | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) |
| Pharyngeal | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) |
| Prostate | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) |
| Upper GI: esophagus | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) |
Q1 = first quartile; Q3 = third quartile
Abbreviations: Gy, Gray; fx, fraction; GE, Gastroesophageal; GI, Gastrointestinal